A Retrospective Study Assessing the Persistence on Golimumab as Second Line Biological Therapy in Patients with Spondyloarthritis (Axial Spondyloarthritis and Psoriatic Arthritis)
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Go-Beyond
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results (n=123) assessing beliefs and satisfaction of patients (SpA) with golimumab therapy, presented at the 19th Annual Congress of the European League Against Rheumatism.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism.